Analysts expect Jounce Therapeutics Inc (NASDAQ:JNCE) to announce $12.80 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Jounce Therapeutics’ earnings, with the highest sales estimate coming in at $15.50 million and the lowest estimate coming in at $11.20 million. Jounce Therapeutics posted sales of $12.99 million during the same quarter last year, which would indicate a negative year over year growth rate of 1.5%. The business is expected to report its next quarterly earnings results on Thursday, March 14th.

According to Zacks, analysts expect that Jounce Therapeutics will report full year sales of $54.57 million for the current fiscal year. For the next year, analysts forecast that the company will post sales of $65.05 million, with estimates ranging from $43.00 million to $86.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.11. The business had revenue of $14.53 million during the quarter, compared to analysts’ expectations of $12.80 million. Jounce Therapeutics had a negative return on equity of 23.27% and a negative net margin of 50.54%.

A number of analysts have commented on JNCE shares. Cowen reissued a “hold” rating on shares of Jounce Therapeutics in a report on Tuesday. Zacks Investment Research lowered Jounce Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Raymond James reduced their target price on Jounce Therapeutics from $13.00 to $12.00 and set an “outperform” rating for the company in a report on Tuesday, October 23rd. ValuEngine raised Jounce Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, HC Wainwright set a $13.00 target price on Jounce Therapeutics and gave the stock a “buy” rating in a report on Wednesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $11.92.

Several institutional investors have recently bought and sold shares of the business. Man Group plc bought a new stake in shares of Jounce Therapeutics in the 3rd quarter worth $1,299,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Jounce Therapeutics in the 3rd quarter worth $231,000. Renaissance Technologies LLC bought a new stake in shares of Jounce Therapeutics in the 3rd quarter worth $1,086,000. JPMorgan Chase & Co. increased its holdings in shares of Jounce Therapeutics by 153.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,029 shares of the company’s stock worth $2,861,000 after purchasing an additional 266,126 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new stake in shares of Jounce Therapeutics in the third quarter worth $677,000. 84.61% of the stock is owned by institutional investors and hedge funds.

NASDAQ:JNCE traded up $0.45 during trading hours on Friday, reaching $4.55. 411,525 shares of the company traded hands, compared to its average volume of 463,132. The stock has a market capitalization of $145.52 million, a price-to-earnings ratio of -7.98 and a beta of 4.97. Jounce Therapeutics has a 1 year low of $3.30 and a 1 year high of $29.25.

About Jounce Therapeutics

Jounce Therapeutics, Inc, a clinical stage immunotherapy company, develops therapies for the treatment of cancer. Its lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.

Featured Article: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with's FREE daily email newsletter.